Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name – Tiogiva®, in UK for the treatment of chronic obstructive pulmonary disease (COPD).
COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissue and a narrowing of the airways, making breathing difficult. There are many different types of the condition, although little is known about what causes this variation and the best way to manage the different versions of the disease1.
According to data from IQVIA, Tiotropium DPI had a market size of US$ 450 Mn in the EU in the 12 month period ended September 2020.
Glenmark’s subsidiary, Glenmark Pharmaceuticals Europe Limited had entered into a strategic, exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and UK in August 2018. Glenmark is planning subsequent launches of the product across markets in Western Europe under the brand name Tiogiva® in Ireland, Sweden, Finland and Norway; Tavulus® in Denmark, Spain and Netherlands; and Tiotropium Glenmark® in Germany.
Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim’s Spiriva® Handihaler® and is used in the treatment of COPD.
This is the second inhalation product in-licensed by Glenmark for the European market after Stalpex® (Fluticasone/ Salmeterol) dry powder inhaler.
“We are glad to introduce Tiogiva®, one of the first bioequivalent drugs to be launched in Europe for treatment of COPD. Respiratory medicine is a key area of focus for Glenmark and the launch of this product will enable us to improve access to COPD treatment by providing an effective and high quality treatment option to patients in UK and Western Europe,” said Achin Gupta, EVP & Business Head of EMEA-L, Glenmark Pharmaceuticals Ltd.